Pharmacokinetic-pharmacodynamic modelling of biomarker response to sitagliptin in healthy volunteers.

  title={Pharmacokinetic-pharmacodynamic modelling of biomarker response to sitagliptin in healthy volunteers.},
  author={Bo-Hyung Kim and Sung Eun Kim and Dong-Woo Kang and Kyoung Soo Lim and Jung-Ryul Kim and I. C. Jang and S Shin and Seo Hyun Yoon and Joo Youn Cho and Kyung-Sang Yu},
  journal={Basic & clinical pharmacology & toxicology},
  volume={113 2},
Pharmacokinetic/pharmacodynamic (PK/PD) models can be useful tools in new drug development and also optimal drug therapy in patients. This study was designed to develop a PK/PD model of sitagliptin based on the physiology of incretin. The PK/PD data included information derived from two different studies. Study 1 was conducted as a one-sequence, three-period, repeated-dose, dose escalation (sitagliptin 25, 50 and 100 mg q.d.) design in twelve healthy volunteers. Study 2 was a first-in-man study… CONTINUE READING